STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1812 by analyst upside · 2026-08-14
BNTX
BioNTech SE
Healthcare · Market Cap $23B · P/E 0x
ANALYST PRICE TARGET
+30.6%
implied upside to consensus target
Current Price $92.12
Consensus Target $120.32
Bull Target $144.22
Bear Target $76.16
Analysts Covering 20
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
14
Hold
5
Sell
0
52-Week Low $79.52
52-Week High $124.0
YTD Return -4.7%
FUNDAMENTALS
Market Cap $23B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-7.69
PEG Ratio 0.05
Dividend Yield N/A
Revenue (TTM) $2.6B
Profit Margin -63.6%
52-WEEK RANGE
52-Week Low $79.52
52-Week High $124.0
Current Price $92.12
Bear Target $76.16
Bull Target $144.22
● Now $92.12 ● Target $120.32
TRADING DATA
Avg Volume 954K
YTD Return -4.7%
Analyst Count 20
Consensus Buy
Upside to Target +30.6%
Last Updated 2026-08-14

ANALYST SUMMARY

BioNTech SE (BNTX) is currently trading at $92.12 with a Wall Street consensus price target of $120.32, implying potential upside of 30.6% over the next 12 months. 20 analysts currently cover BNTX, with a consensus rating of Buy - 75% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $144.22, while the most cautious has a target of $76.16.

BNTX operates in the Healthcare sector with a market capitalisation of $23B. The stock is down 4.7% year-to-date and is currently trading near the lower end of its 52-week range of $79.52 – $124.0.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for BNTX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

UBS ↑ Upgrade
Neutral → Buy 2026-05-27 33% win rate (6 calls)
Bernstein ● Initiated
Market Perform 2026-05-22 Building track record
Canaccord Genuity - Reiterated
Buy → Buy 2026-05-06 Building track record
Wells Fargo - Reiterated
Overweight → Overweight 2026-05-06 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-04-27 31% win rate (48 calls)
Morgan Stanley - Reiterated
Overweight → Overweight 2026-04-10 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-03-31 31% win rate (48 calls)
Morgan Stanley - Reiterated
Overweight → Overweight 2026-03-11 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
52
out of 100
Coverage depth
23/30
Consensus clarity
15/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →